Diabetes aktuell 2012; 10(3): 118-122
DOI: 10.1055/s-0032-1320052
Schwerpunkt
© Georg Thieme Verlag Stuttgart · New York

Epidemiologische Forschung – Deutsches Zentrum für Diabetesforschung

Epidemiological Research – German Center for Diabetes Research
Matthias Schulze
1   Abteilung Molekulare Epidemiologie, Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
,
Annette Peters
2   Institute of Epidemiology II, Helmholtz Zentrum München – Deutsches Zentrum für Gesundheit und Umwelt
› Author Affiliations
Further Information

Publication History

Publication Date:
11 June 2012 (online)

Die epidemiologische Forschung im Deutschen Zentrum für Diabetesforschung DZD stützt sich auf bereits existierende, große Kohortenstudien, die in den letzten Jahren einen Schwerpunkt auf die Erforschung der Störungen des Metabolismus und die Entwicklung des Diabetes gelegt haben. Diese Studien werden federführend von dem Deutschen Institut für Ernährungsforschung (DIfE) in der Region Potsdam und vom Helmholtz Zentrum München (HMGU) in der Region Augsburg durchgeführt. Beide DZD-Zentren unterhalten gut etablierte Kooperationen mit anderen DZD-Partnern, insbesondere zwischen DIfE und der Universität Tübingen sowie zwischen der HMGU und dem Deutschen Diabetes Zentrum in Düsseldorf. Im Folgenden beschreiben wir die beiden Kohortenstudien und stellen neue Ergebnisse aus den beiden Studien vor. Im Ausblick beschreiben wir die neuen Projekte im Rahmen des DZD.

The epidemiological research in the German Center for Diabetes Research (GCDR) is based on already existing, large cohort studies that in the past few years have placed their focus on research into metabolic disorders and the development of diabetes. These studies were carried out under the direction of the German Institute for Nutritional Research (GINR) in the Potsdam region and the Helmholtz Center Munich (HCM) in the Augsburg region. Both diabetes centers are involved in well-established cooperative projects with other GCDR partners, worthy of special mention are those between GINR and the University of Tübingen and between HCM and the German Diabetes Center in Düsseldorf. In the present article we describe the two cohort studies and present new results from the two trials. We also prospectively mention new projects within the framework of the GCDR.

 
  • Literatur

  • 1 Boeing H, Wahrendorf J, Becker N. EPIC-Germany-A source for studies into diet and risk of chronic diseases. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999; 43: 195-204
  • 2 Schulze MB, Hoffmann K, Boeing H et al. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 2007; 30: 510-515
  • 3 Kerner W, Brückel J. Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2010; 5 (Suppl. 02)
  • 4 Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev 2011; 33: 46-62
  • 5 Heidemann C, Boeing H, Pischon T et al. Association of a diabetes risk score with risk of myocardial infarction, stroke, specific types of cancer, and mortality: a prospective study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort. Eur J Epidemiol 2009; 24: 281-288
  • 6 Schulze MB, Weikert C, Pischon T et al. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. Diabetes Care 2009; 32: 2116-2119
  • 7 Schulze MB, Thorand B, Fritsche A et al. Body adiposity index, body fat content and incidence of type 2 diabetes. Diabetologia 17.02.2012; 55 [Epub ahead of print]
  • 8 Schulze MB, Schulz M, Heidemann C et al. Fiber and magnesium intake and incidence of type 2 diabetes: a prospective study and meta-analysis. Arch Intern Med 2007; 167: 956-965
  • 9 Heidemann C, Hoffmann K, Spranger J et al. A dietary pattern protective against type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study cohort. Diabetologia 2005; 48: 1126-1134
  • 10 Ford ES, Bergmann MM, Kroger J et al. Healthy living is the best revenge: findings from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. Arch Intern Med 2009; 169: 1355-1362
  • 11 Kroger J, Zietemann V, Enzenbach C et al. Erythrocyte membrane phospholipid fatty acids, desaturase activity, and dietary fatty acids in relation to risk of type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr 2011; 93: 127-142
  • 12 Stefan N, Fritsche A, Weikert C et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008; 57: 2762-2767
  • 13 Holle R, Happich M, Lowel H, Wichmann HE. KORA-a research platform for population based health research. Gesundheitswesen 2005; 67 (Suppl. 01)
  • 14 Meisinger C, Strassburger K, Heier M et al. Prevalence of undiagnosed diabetes and impaired glucose regulation in 35–59-year-old individuals in Southern Germany: the KORA F4 Study. Diabet Med 2010; 27: 360-362
  • 15 Rathmann W, Strassburger K, Heier M et al. Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabet Med 2009; 26: 1212-1219
  • 16 Rathmann W, Kowall B, Heier M et al. Prediction models for incident Type 2 diabetes mellitusin the older population: KORA S4/F4 cohort study. Diabet Med 2010; 27: 1116-1123
  • 17 Stockl D, Doring A, Peters A, Thorand B, Heier M, Huth C, Stockl H, Rathmann W, Kowall B, Meisinger C. Age at menarche is associated with prediabetes and diabetes in women (aged 32–81 years) from the general population: the KORA F4 Study. Diabetologia [online first] 2011; 54
  • 18 Thorand B, Zierer A, Huth C et al. Effect of serum 25-hydroxyvitamin D on risk for type 2 diabetes may be partially mediated by subclinical inflammation: results from the MONICA/KORA Augsburg study. Diabetes Care 2011; 34: 2320-2322
  • 19 Suhre K, Shin SY, Petersen AK et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature 2011; 477: 54-60